<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00552747</url>
  </required_header>
  <id_info>
    <org_study_id>fenofibrate</org_study_id>
    <nct_id>NCT00552747</nct_id>
  </id_info>
  <brief_title>Effect of Fenofibrate on Endothelial Function and High-density Lipoproteins (HDL)in Patients With Coronary Heart Disease</brief_title>
  <official_title>The Effect of Fenofibrate on Endothelial Function and HDL in Patients With Coronary Heart Disease and LDL-C at Goal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart Institute, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Heart Institute, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fenofibrate is a drug that acts on the PPAR alpha receptors, increasing HDL-cholesterol and
      decreasing triglyceride levels. The interaction with these receptors has antiatherogenic
      actions by regulating the expression con key proteins that participate in vascular
      inflammation, plaque stability and thrombosis.

      Fenofibrate reduces triglycerides and increases HDL-C in plasma. It also decreases small,
      dense LDL particles. The use of this drug has resulted in improvement of vascular function
      measured by endothelial function. Our hypotheses state that fenofibrate will improve:
      endothelial function, improve HDL antioxidant capacity and size distribution towards a
      predominance of small HDL particles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with stable coronary heart disease, with LDL-C levels at goal will be invited to
      participate in this randomized, double blind study to receive either placebo or fenofibrate
      in addition to their statin therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial function</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HDL particle distribution</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL associated antioxidant capacity</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fenofibrate 160 mg capsules (QD) Taken once daily with the largest meal of the day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (capsules identical to those of fenofibrate) taken once daily (QD)with the largest meal of the day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenofibrate</intervention_name>
    <description>fenofibrate 160 mg capsules qd</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>capsules placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients 18-60 years of age

          -  Stable coronary heart disease (no cardiovascular event 3 months prior to enrollment)

          -  Stable lipid-modifying drug therapy (previous 2 months)

          -  Low-dose statin therapy with LDL-C at goal (&lt; 100 mg/dl)

          -  Triglyceride levels 151-500 mg/dl

          -  HDL-C levels &lt;40 mg/dl

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Uncontrolled hypertension Systolic blood pressure &gt;160 mmHg and/or diastolic blood
             pressure &gt;100 mmHg

          -  Subjects with renal (serum creatinine &gt;1.5 times the upper limit of normal (ULN)),
             hepatobiliary (cholelithiasis, biliary cirrhosis, AST and/or ALT &gt;2x ULN) or active
             thyroid disease (TSH &gt;1.5x ULN or &lt;0.05 uUI/ml)

          -  Hypersensitivity to fenofibrate or to any other component of its formula

          -  History of photoallergic reaction or phototoxicity to fenofibrate or ketoprofen
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Posadas-Romero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pedro Reyes, MD</last_name>
    <role>Study Director</role>
    <affiliation>head bioethics committee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endocrinology Department National Institute of Cardiology Ignacio Chavez</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.cardiologia.org.mx</url>
    <description>National Institute of Cardiology Mexico City MEXICO</description>
  </link>
  <reference>
    <citation>Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 Nov 19;344(8934):1383-9.</citation>
    <PMID>7968073</PMID>
  </reference>
  <reference>
    <citation>Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301-7.</citation>
    <PMID>7566020</PMID>
  </reference>
  <reference>
    <citation>Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 3;335(14):1001-9.</citation>
    <PMID>8801446</PMID>
  </reference>
  <reference>
    <citation>Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998 May 27;279(20):1615-22.</citation>
    <PMID>9613910</PMID>
  </reference>
  <reference>
    <citation>Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 Apr 8;350(15):1495-504. Epub 2004 Mar 8. Erratum in: N Engl J Med. 2006 Feb 16;354(7):778.</citation>
    <PMID>15007110</PMID>
  </reference>
  <reference>
    <citation>LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 Apr 7;352(14):1425-35. Epub 2005 Mar 8.</citation>
    <PMID>15755765</PMID>
  </reference>
  <reference>
    <citation>Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989 Jan;79(1):8-15.</citation>
    <PMID>2642759</PMID>
  </reference>
  <reference>
    <citation>Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996 Apr;3(2):213-9.</citation>
    <PMID>8836866</PMID>
  </reference>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2007</study_first_submitted>
  <study_first_submitted_qc>November 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2007</study_first_posted>
  <last_update_submitted>March 9, 2011</last_update_submitted>
  <last_update_submitted_qc>March 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Carlos Posadas-Romero MD</name_title>
    <organization>National Institute of Cardiology</organization>
  </responsible_party>
  <keyword>fenofibrate</keyword>
  <keyword>coronary heart disease</keyword>
  <keyword>mixed hyperlipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

